CRISPR Therapeutics AG (CRSP) Payables (2015 - 2026)

CRISPR Therapeutics AG has disclosed Payables across 12 years of filings, most recently posting $13.6 million for Q1 2026.

• Payables for Q1 2026 came in at $13.6 million, up 4.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.6 million (up 4.46% YoY), and the FY2025 annual result was $11.1 million, down 24.28% from the prior year.
• Payables came in at $13.6 million for Q1 2026 at CRISPR Therapeutics AG, up from $11.1 million in the prior quarter.
• In the past five years, Payables ranged from a high of $45.2 million in Q1 2023 to a low of $9.5 million in Q2 2024.
• The 5-year median for Payables is $16.5 million (2024), against an average of $21.4 million.
• Across the five-year window, Payables surged 215.87% in 2022 and plunged 65.74% in 2024, its largest moves.
• CRISPR Therapeutics AG's Payables stood at $27.4 million in 2022, then jumped by 39.08% to $38.1 million in 2023, then plunged by 61.44% to $14.7 million in 2024, then slipped by 24.28% to $11.1 million in 2025, then rose by 22.53% to $13.6 million in 2026.
• The last three Payables figures came in at $13.6 million (Q1 2026), $11.1 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.